Literature DB >> 32410903

Case Report: Postvaccination Anti-Myelin Oligodendrocyte Glycoprotein Neuromyelitis Optica Spectrum Disorder: A Case Report and Literature Review of Postvaccination Demyelination.

Neha Kumar, Kelsey Graven, Nancy I Joseph, John Johnson, Scott Fulton, Robert Hostoffer, Hesham Abboud.   

Abstract

Stimulation of the immune response after vaccination can occasionally result in adverse effects, including demyelination of the central nervous system. The most common presentation of postvaccination demyelination is acute disseminated encephalomyelitis, but cases of optic neuritis, transverse myelitis, and multiple sclerosis relapses have been reported. More recently, an increasing number of postvaccination neuromyelitis optica spectrum disorder (NMOSD) cases have surfaced in the literature, especially in patients with aquaporin-4 antibodies. In this article, we report an unusual case of myelin oligodendrocyte glycoprotein antibody-related NMOSD after the receipt of multiple vaccines in a first-trimester pregnant woman from Africa. We review the reported cases of postvaccination demyelination in the past decade, with a focus on the relationship between NMOSD and vaccination in patients with aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies. Finally, we discuss the clinical relevance of the present case and similar reported cases as it relates to patient care in the neuroimmunology clinic and identify potential areas for future research.
© 2020 Consortium of Multiple Sclerosis Centers.

Entities:  

Keywords:  Anti-myelin oligodendrocyte glycoprotein (MOG); Multiple sclerosis (MS); Neuromyelitis optica

Year:  2020        PMID: 32410903      PMCID: PMC7204366          DOI: 10.7224/1537-2073.2018-104

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  21 in total

Review 1.  HLA, molecular mimicry and multiple sclerosis.

Authors:  R Liblau; A M Gautam
Journal:  Rev Immunogenet       Date:  2000

2.  Post-influenza vaccine chronic inflammatory demyelinating polyneuropathy.

Authors:  J M Brostoff; Y Beitverda; J Birns
Journal:  Age Ageing       Date:  2007-11-09       Impact factor: 10.668

3.  Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Authors:  Mauricio F Farez; Jorge Correale; Melissa J Armstrong; Alexander Rae-Grant; David Gloss; Diane Donley; Yolanda Holler-Managan; Norman J Kachuck; Douglas Jeffery; Maureen Beilman; Gary Gronseth; David Michelson; Erin Lee; Julie Cox; Tom Getchius; James Sejvar; Pushpa Narayanaswami
Journal:  Neurology       Date:  2019-08-28       Impact factor: 9.910

4.  Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis.

Authors:  Luana Michelli Oliveira; Samira Luisa Apóstolos-Pereira; Milena Sales Pitombeira; Pedro Henrique Bruel Torretta; Dagoberto Callegaro; Douglas Kazutoshi Sato
Journal:  Mult Scler       Date:  2018-11-12       Impact factor: 6.312

5.  Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange.

Authors:  Hesham Abboud; Alex Petrak; Maureen Mealy; Sarana Sasidharan; Laila Siddique; Michael Levy
Journal:  Mult Scler       Date:  2015-04-28       Impact factor: 6.312

6.  Vaccinations and risk of central nervous system demyelinating diseases in adults.

Authors:  Frank DeStefano; Thomas Verstraeten; Lisa A Jackson; Catherine A Okoro; Patti Benson; Steven B Black; Henry R Shinefield; John P Mullooly; William Likosky; Robert T Chen
Journal:  Arch Neurol       Date:  2003-04

Review 7.  Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis.

Authors:  Anthony Lopez; Xavier Mariette; Hervé Bachelez; Alexandre Belot; Bernard Bonnotte; Eric Hachulla; Morad Lahfa; Olivier Lortholary; Pierre Loulergue; Stéphane Paul; Xavier Roblin; Jean Sibilia; Mariela Blum; Silvio Danese; Stefanos Bonovas; Laurent Peyrin-Biroulet
Journal:  J Autoimmun       Date:  2017-04-02       Impact factor: 7.094

8.  Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases.

Authors:  Annette Langer-Gould; Lei Qian; Sara Y Tartof; Sonu M Brara; Steve J Jacobsen; Brandon E Beaber; Lina S Sy; Chun Chao; Rulin Hechter; Hung Fu Tseng
Journal:  JAMA Neurol       Date:  2014-12       Impact factor: 18.302

Review 9.  The spectrum of post-vaccination inflammatory CNS demyelinating syndromes.

Authors:  Dimitrios Karussis; Panayiota Petrou
Journal:  Autoimmun Rev       Date:  2014-03       Impact factor: 9.754

10.  The Impacts of Influenza Infection and Vaccination on Exacerbation of Myasthenia Gravis.

Authors:  Hung Youl Seok; Ha Young Shin; Jong Kuk Kim; Byoung Joon Kim; Jeeyoung Oh; Bum Chun Suh; Sun Young Kim; Sa Yoon Kang; Suk Won Ahn; Jong Seok Bae; Byung Jo Kim
Journal:  J Clin Neurol       Date:  2017-10       Impact factor: 3.077

View more
  10 in total

1.  Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and Transverse Myelitis Probably Associated With SARS-CoV-2 mRNA Vaccines: Two Case Reports.

Authors:  Jonathan Morena; Tirisham V Gyang
Journal:  Neurohospitalist       Date:  2022-04-17

2.  Myelin Oligodendrocyte Glycoprotein Antibody Disease After COVID-19 Vaccination - Causal or Incidental?

Authors:  Vineet Sehgal; Priyanshu Bansal; Shaifali Arora; Saniya Kapila; Gaganpreet S Bedi
Journal:  Cureus       Date:  2022-07-19

Review 3.  MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.

Authors:  S Jarius; N Bieber; J Haas; B Wildemann
Journal:  J Neurol       Date:  2022-06-23       Impact factor: 6.682

4.  COVID-19 vaccine associated demyelination & its association with MOG antibody.

Authors:  M Netravathi; Kamakshi Dhamija; Manisha Gupta; Arina Tamborska; A Nalini; V V Holla; L K Nitish; Deepak Menon; P K Pal; V Seena; Ravi Yadav; M Ravindranadh; Arshad Faheem; J Saini; Anita Mahadevan; Tom Solomon; Bhagteshwar Singh
Journal:  Mult Scler Relat Disord       Date:  2022-03-13       Impact factor: 4.808

5.  Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD.

Authors:  Alessandro Dinoto; Elia Sechi; Sergio Ferrari; Alberto Gajofatto; Riccardo Orlandi; Paolo Solla; Alessandra Maccabeo; Giorgia Teresa Maniscalco; Vincenzo Andreone; Arianna Sartori; Paolo Manganotti; Sarah Rasia; Ruggero Capra; Chiara Rosa Mancinelli; Sara Mariotto
Journal:  Mult Scler Relat Disord       Date:  2021-11-22       Impact factor: 4.339

6.  Post-COVID-19 Longitudinally Extensive Transverse Myelitis with Myelin Oligodendrocyte Glycoprotein Antibodies.

Authors:  Ellen Yang; Adnan Husein; Jose Martinez-Perez; Terrence Li
Journal:  Case Rep Neurol Med       Date:  2022-04-05

7.  MOG Antibody-Associated Disorders Following SARS-CoV-2 Vaccination: A Case Report and Literature Review.

Authors:  Yuki Matsumoto; Ayane Ohyama; Takafumi Kubota; Kensuke Ikeda; Kimihiko Kaneko; Yoshiki Takai; Hitoshi Warita; Toshiyuki Takahashi; Tatsuro Misu; Masashi Aoki
Journal:  Front Neurol       Date:  2022-03-01       Impact factor: 4.003

Review 8.  COVID-19 Vaccination and The Eye.

Authors:  Michael T M Wang; Rachael L Niederer; Charles N J McGhee; Helen V Danesh-Meyer
Journal:  Am J Ophthalmol       Date:  2022-02-25       Impact factor: 5.488

9.  Measles-rubella vaccine-associated MOG-antibody positive acute demyelinating encephalomyelitis with optic neuritis in a child.

Authors:  Madhumati Otiv; Abhijeet Botre; Pawan Shah
Journal:  Ther Adv Vaccines Immunother       Date:  2022-08-09

10.  MOG antibody-associated encephalomyelitis mimicking bacterial meningomyelitis following ChAdOx1 nCoV-19 vaccination: a case report.

Authors:  Jordi Kühne Escolà; Cornelius Deuschl; Andreas Junker; Fabian Dusse; Refik Pul; Christoph Kleinschnitz; Martin Köhrmann; Benedikt Frank
Journal:  Ther Adv Neurol Disord       Date:  2022-01-19       Impact factor: 6.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.